LAWRENCE, Mass., Jan. 13, 2015 /PRNewswire/ -- NxStage® Medical,
Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis
products, today increased its revenue guidance for the fourth
quarter and fiscal year ended December 31,
2014.
For the fourth quarter of 2014, the Company expects to deliver
total revenue above $78 million,
exceeding the top end of its previously announced guidance range
for revenue to be between $74.5 to $76.5
million. This performance is expected to reflect above 18%
growth in the Home when compared with the fourth quarter of
2013.
For the full-year 2014, the Company expects to deliver total
revenue above $299 million, exceeding
the top end of its previously increased guidance range for revenue
to be between $296 to $298 million.
Annual Home revenue growth for 2014 is expected to be approximately
18%, exceeding the Company's previously announced guidance of 15%
growth.
The Company also expects net loss for the fourth quarter and the
full-year 2014 to be at the favorable end of its previously
announced guidance ranges of $5 to $7
million and $24 to $26
million, respectively.
"Heading into 2014, we detailed a clear strategy to accelerate
growth and adoption in the Home. We solidly executed against
this strategy, delivering greater than 15% growth in Home within
each quarter and ending the year well ahead of our 15% annual
growth target," stated Jeffrey H.
Burbank, Chief Executive Officer. "2014 provides a great
foundation upon which we expect to build on with a goal of 15%
annual Home revenue growth in 2015 and beyond."
Management will be presenting at the 33rd Annual J.P. Morgan
Healthcare Conference in San Francisco,
CA on Thursday, January
15th at 12:00 p.m.
PST. A webcast of the presentation will be made available at
http://ir.nxstage.com at the time of the presentation. The Company
plans to announce its financial results for the fourth quarter and
fiscal year ended December 31, 2014
on Thursday, February 26, 2015 at
9:00 am ET.
About NxStage
NxStage Medical, Inc. (Nasdaq: NXTM) is
a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops,
manufactures and markets innovative products for the treatment of
ESRD and acute kidney failure. For more information on NxStage and
its products, please visit the Company's website at
www.nxstage.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Examples of these
forward-looking statements include statements as to the anticipated
demand for the Company's products, anticipated operating results,
including revenues, loss, gross margin, and other expectations as
to future operating results. All forward-looking statements involve
risks, uncertainties and contingencies, many of which are beyond
NxStage's control, which may cause actual results, performance, or
achievements to differ materially from anticipated results,
performance or achievements, including market acceptance and demand
for NxStage's products domestically and internationally, growth in
home and/or more frequent hemodialysis, unanticipated difficulties
in achieving operational efficiencies and cost reductions, changes
in reimbursement for home and more frequent hemodialysis, changes
in the regulatory environment, changes in the historical purchasing
patterns and preferences of our customers, including DaVita
Healthcare Partners Inc. and Fresenius Medical Care, including in
response to the Company's NxStage Kidney Care initiative, and
certain other factors that may affect future operating results and
which are detailed in NxStage's filings with the Securities and
Exchange Commission, including its Quarterly Report on Form 10-Q
for the quarter ended September 30,
2014.
In addition, the statements in this press release represent
NxStage's expectations and beliefs as of the date of this press
release. NxStage anticipates that subsequent events and
developments may cause these expectations and beliefs to change.
However, while NxStage may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so, whether as a result of new information,
future events, or otherwise. These forward-looking statements
should not be relied upon as representing NxStage's expectations or
beliefs as of any date subsequent to the date of this press
release.
Contact:
Kristen K. Sheppard, Esq.
VP,
Investor Relations
ksheppard@nxstage.com
Logo -
http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nxstage-increases-revenue-guidance-for-the-fourth-quarter-and-full-year-2014-300019210.html
SOURCE NxStage Medical Inc.